21 Invest is proud to announce the launch of the 21 Invest Healthcare fund, achieving a first closing of nearly €M 70 and targeting a hard cap of €M 150. This marks the group’s first investment vehicle dedicated to the healthcare sector.

21 Invest Healthcare follows an impact investment strategy and is Article 9 SFDR compliant. The fund will invest in high-growth potential Italian and European companies focused on innovative products and services that enhance the well-being of individuals and animals. Target sub-sectors include healthcare, wellness, and wellbeing, covering areas such as nutraceuticals, advanced cosmetics, veterinary services, and related industries. The investments will have a ticket size between €M 10 and €M 15.

A dedicated team with extensive private equity experience and deep expertise in investing in the healthcare sector will oversee the fund’s activities. The team is led by partners Stefania Petruccioli, Alessandro Damiano, and Fabio Parisi, along with principal Michele Fodde.

They join 21 Invest’s established team, which now includes over 50 professionals across Italy, France, and Poland.

The decision to focus on the healthcare sector builds on the group’s proven track record, with successful investments in companies like ProductLife Group and SIFI.

Alessandro Benetton, Founding Managing Partner of 21 Invest, comments:
“This marks an important achievement for 21 Invest, as we strengthen our solid core values while projecting ourselves into a future where the healthcare sector will play an increasingly central role, requiring commitment and focus. This fund represents our contribution to a critical field for society and collective well-being, leveraging the expertise we have developed over the years in Italy and France.”